Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Other Events

0

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Other Events
Item 8.01 Other Events.

On November10, 2017, Infinity Pharmaceuticals, Inc. issued a press release announcing data from its Phase 1/1b clinical study of IPI-549, a selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibitor. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on websites referenced in the press release is not incorporated herein.

Item 8.01 Financial Statements and Exhibits.

(d) The following exhibit is included in this report:

Exhibit

No.

Description

99.1 Press Release dated November10, 2017


INFINITY PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 d491319dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting – IPI-549 Was Well Tolerated and Demonstrated Clinical Activity,…
To view the full exhibit click here

About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

An ad to help with our costs